MedTrace Logo

Mobile App for Improving Adherence of Rivoxaban (RIVOX-AF)

NCT05557123 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 637

Last updated 2026-05-19

No results posted yet for this study

Summary

RIVOX-AF study is a prospective, multicenter, randomized controlled study in which patients with AF are allocated to medication-app group or conventional treatment group. The App based feed-back algorithm will provide the patients with check taking drug or reminding of taking drug.

Conditions

Interventions

DEVICE

MEDI-app

MEDI-app based feedback algorithm. The app based feedback algorithm will check and remind the patients of taking medication.

Sponsors & Collaborators

  • SAMJIN PHARM

    collaborator UNKNOWN

  • Seoul National University Bundang Hospital

    lead OTHER

Principal Investigators

  • Dong-Ju Choi, MD, PhD · Seoul National Univeristy Bundang Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-03-10
Primary Completion
2025-12-16
Completion
2025-12-16

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05557123 on ClinicalTrials.gov